Pillarene-based glutathione-responsive sulfur dioxide-releasing prodrugs and their applications
By introducing 2,4-dinitrobenzene sulfonate on the column aromatics and complexing with targeted molecules, combining with tetrastyrene to glycol chains, forming SO2 prodrug nanoparticles that are sensitive to glutathione, solving The gap in SO2 release research based on columnar aromatic hydrocarbons has been achieved, efficient tumor treatment and targeted transport, and improved the treatment efficiency of SO2 and the biocompatibility of nanoparticles.
Patent Information
- Application Number
- CN202310049630.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-02-01
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2043-02-01
AI Technical Summary
There is currently a lack of research on nanoparticles based on columnar aromatics as key compounds for SO2 release, especially in the field of gas therapy, especially in tumor therapy, which is difficult to effectively utilize the therapeutic efficiency of SO2.
A SO2 prodrug sensitive to glutathione (GSH) was constructed by introducing 2,4-dinitrobenzene sulfonate on column aromatics and was constructed with the targeting molecule amino-polyethylene glycol-folic acid (NH2) -PEG-FA) complexing, combined with tetrastyrene-connected glycol chain wrapping to form nanoparticles, achieving responsive release and targeted transport of SO2.
The therapeutic efficiency of SO2 is improved, the therapeutic effect of SO2 is enhanced by depleting GSH in tumor cells, and the dispersion and biocompatibility of nanoparticles are improved through targeted transport and fluorescent labeling.
Smart Images

Figure CN116283675B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedicine, and in particular relates to a prodrug of glutathione based on pillar aromatic hydrocarbons that releases sulfur dioxide in response and an application thereof. Background Art
[0002] Through continuous development, macrocyclic molecules have developed rapidly in the field of supramolecular chemistry. Since 2008, the fifth generation of macrocyclic molecules, pillararenes, have entered people's field of vision. In just a few years, researchers have made great achievements in the synthesis, functional modification, host-guest properties and applications of pillararenes. Pillararenes are a macrocyclic host molecule that connects hydroquinone or hydroquinone to the para position on the benzene ring through a methylene group. Compared with previous generations of macrocyclic molecules, pillararenes are simple to synthesize, easy to modify, have a rigid electron-rich cavity structure and reversible self-assembly, so more and more people are applying them in the biological field.
[0003] In the field of cancer treatment, gas therapy has attracted widespread attention as a new type of method. SO2 is often considered an air pollutant, but SO2 can also be produced by the body's metabolic function. In recent years, many studies have shown that SO2 also plays an extremely important role in regulating the cardiovascular system. Therefore, after NO, CO2 and H2S, SO2 is considered to be the fourth gaseous transmitter. In cells, SO2 can consume glutathione (GSH) and produce reactive oxygen species (ROS), while excessive SO2 can cause damage to the body and induce cell apoptosis. In the field of gas therapy, Dong et al. prepared a pH / GSH-responsive SO2-releasing nanoplatform based on boron bispyrromethene (BODIPY), but there is currently no research on nanoparticles based on pillar aromatics as key compounds for releasing SO2. Summary of the invention
[0004] The purpose of the present invention is to provide a prodrug of glutathione responsive to release SO2 based on pillar aromatic hydrocarbons and its application.
[0005] In order to achieve the above object, the present invention adopts the following technical solutions:
[0006] A prodrug that releases SO2 in response to glutathione, the structural formula of which is shown below:
[0007]
[0008] A tumor therapeutic drug, comprising the above-mentioned prodrug.
[0009] A nanoparticle comprises an inner core and a hydrophilic outer shell, wherein the hydrophilic outer shell is wrapped around the inner core;
[0010] The core is formed by complexing the above-mentioned prodrug with NH2-PEG-FA;
[0011] The hydrophilic shell is a tetraphenylethylene connected to a glycol chain, and the structural formula of the tetraphenylethylene connected to a glycol chain is shown below:
[0012]
[0013] The preparation process of the above nanoparticles is as follows: the above prodrug is dissolved in acetone, then an aqueous solution of amino-polyethylene glycol-folic acid (NH2-PEG-FA) is added dropwise, and then an aqueous solution of tetraphenylethylene glycol chains is added dropwise, after stirring at room temperature for 24 hours, the acetone is removed, and the nanoparticles are obtained after dialysis. The weight ratio of the prodrug, NH2-PEG-FA and tetraphenylethylene glycol chains is 4:1:8.
[0014] The application of the above nanoparticles in the preparation of tumor therapeutic drugs.
[0015] A tumor treatment drug comprises the above-mentioned nanoparticles.
[0016] The present invention constructs a SO2 prodrug sensitive to glutathione (GSH) by introducing 2,4-dinitrobenzene sulfonate into pillar aromatic hydrocarbons, and can improve the therapeutic efficiency of SO2 by consuming GSH in tumor cells. Furthermore, the targeting molecule amino-polyethylene glycol-folic acid (NH2-PEG-FA) is complexed with the pillar aromatic hydrocarbon prodrug by utilizing the host-guest interaction, so as to achieve targeted drug transport; since tetraphenylethylene glycol chain (TPE-PEG) is non-toxic and has fluorescence, by wrapping the hydrophilic tetraphenylethylene glycol chain (TPE-PEG) into the novel pillar [5] aromatic hydrocarbons, the nanoparticles can have excellent dispersibility, biocompatibility and fluorescence performance in water. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 This is the hydrogen nuclear magnetic resonance spectrum of the novel column [5] aromatic hydrocarbon in Example 1.
[0018] Figure 2 The SO2 release results of the new column [5] aromatics in Example 1.
[0019] Figure 3 This is the nuclear magnetic resonance hydrogen spectrum of the model compound ammonium hexafluorophosphate salt of the new column [5] aromatic hydrocarbon and the targeting molecule NH2-PEG-FA in Example 2, where a is ammonium hexafluorophosphate salt, b is column [5] aromatic hydrocarbon and ammonium hexafluorophosphate salt, and c is column [5] aromatic hydrocarbon.
[0020] Figure 4 (a) is a scanning electron microscope image of PSTPE in Example 3 and (b) is a dynamic light scattering image of PSTPE.
[0021] Figure 5 The cytotoxicity test results of rat glioma (C6) cells (a) and human breast cancer (MCF-7) cells (b) in Example 4 are shown. DETAILED DESCRIPTION
[0022] The present invention is further described in detail below in conjunction with the accompanying drawings and specific examples, but it should not be construed as limiting the present invention. Without departing from the spirit and substance of the present invention, the modification or replacement of the method, steps or conditions of the present invention all belong to the scope of the present invention. The experimental methods and reagents without specifying the specific conditions in the examples are all in accordance with the conventional conditions in the art.
[0023] Example 1
[0024] Synthesis of novel column[5]aromatic hydrocarbons
[0025]
[0026] Dissolve 100 mg of P1 (0.14 mmol) in 100 mL of dichloromethane, gradually drip into a Shrek bottle under nitrogen protection, stir in an ice bath, add 400 μL of triethylamine (2.8 mmol), then dissolve 79.78 mg of di, tetra-dinitrobenzenesulfonyl chloride (0.3 mmol) in 50 mL of dichloromethane, and slowly drip into the above solution. Fill with nitrogen again, stir at room temperature for 12 hours, quench the triethylamine with deionized water, extract the product with dichloromethane, and further purify by column chromatography (petroleum ether: ethyl acetate = 50:1) to obtain a new column [5] aromatic hydrocarbon.
[0027] Figure 1 The H NMR spectrum of the novel column [5] aromatics confirmed the successful preparation of the target compound.
[0028] Since the novel pillar[5]arene is connected to 2,4-dinitrobenzenesulfonic acid groups on both sides, it will break in the presence of glutathione to release sulfur dioxide (SO2). In order to study the response characteristics of pillar[5]arene to GSH, 7-(diethylamino)coumarin (DEACA) was used as a selective fluorescent probe to quantify the release of SO2 by detecting bisulfite in PBS solution.
[0029] First, column [5] aromatics were prepared into aqueous solutions with different concentrations (0.025, 0.05, 0.1 mg / mL), and the same concentration of GSH (5 mM) was added for incubation for 1 hour, and then 5 μM DEACE fluorescent probe was added. The solution was tested at different time points (1, 2, 3, 4, 5, 6, 8 h) using a fluorescence spectrophotometer. It can be seen that with the increase of time, the release of SO2 increases accordingly. At the same time, the higher the concentration, the more SO2 is released; after 8 hours of accumulation, 0.1 mg / mL column [5] aromatics can release 108.3 μM SO2. At the same time, a 0.1 mg / mL columnar aromatic solution was prepared. After adding different concentrations (0.1, 0.25, 0.5 mg / mL) of GSH aqueous solution and incubating for 1 hour, 5 μM DEACA fluorescent probe was added and the solution was tested at different time points (1, 2, 3, 4, 5, 6, 8 hours). As time goes by, the higher the concentration of GSH, the more SO2 is released by columnar aromatics, and the highest release rate can reach 79.33%. Figure 2 shown.
[0030] Example 2
[0031] Simulated complexation of novel column[5]arene with model compound ammonium hexafluorophosphate
[0032] Ammonium hexafluorophosphate was used as a model compound for the targeting molecule amino-polyethylene glycol-folic acid (NH2-PEG-FA), and nuclear magnetic resonance hydrogen spectroscopy was used to investigate the simulated complexation between the model compound ammonium hexafluorophosphate and the novel column [5] aromatic hydrocarbon. 4.08 mg of ammonium hexafluorophosphate (10 μM) and 8.16 mg of the novel column [5] aromatic hydrocarbon (10 μM) were dissolved in a mixed solution of 0.4 mL of heavy water and 0.2 mL of DMSO, respectively. Then, the ammonium hexafluorophosphate (2.45 mg, 6 μM) dissolved in 0.4 mL of heavy water and the novel column [5] aromatic hydrocarbon (3.26 mg, 4 μM) dissolved in 0.2 mL of DMSO were mixed evenly. Comparing the nuclear magnetic hydrogen spectra of the three compounds, it was found that the peak position of the ammonium hexafluorophosphate of the mixed group shifted toward the high field direction, indicating that the model compound ammonium hexafluorophosphate and the column [5] aromatic hydrocarbon were successfully complexed by the host and the guest, such as Figure 3 shown.
[0033] Example 3
[0034] Preparation of novel self-assembled nanoparticles of pillar[5]arene and tetraphenylethylene linked to glycol chains
[0035] Dissolve 4 mg of column [5] aromatic hydrocarbon in 50 μL of acetone, stir at room temperature for 20 minutes, then dissolve 1 mg of amino-polyethylene glycol-folic acid (NH2-PEG-FA) in 1 mL of deionized water and add dropwise to the above solution. Dissolve 8 mg of tetraphenylethylene glycol chain in 5.5 mL of aqueous solution and add dropwise to the above solution through a syringe pump. After stirring at room temperature for 24 hours, use nitrogen bubbling to accelerate the volatilization of acetone. Place the reaction solution in a dialysis bag (molecular weight 3500) and dialyze with deionized water for 24 hours to obtain targeted PSTPE-FA nanoparticles.
[0036] 4 mg of column [5] aromatic hydrocarbon was dissolved in 50 μL of acetone, stirred at room temperature for 20 minutes, 8 mg of tetraphenylethylene glycol chain was dissolved in 5.5 mL of aqueous solution, and then added dropwise to the above solution through a syringe pump. After stirring at room temperature for 24 hours, nitrogen bubbling was used to accelerate the volatilization of acetone. The reaction solution was placed in a dialysis bag (molecular weight 3500) and dialyzed with deionized water for 24 hours to obtain PSTPE nanoparticles.
[0037] 200 μL of PSTPE nanoparticles (2 mg / mL) were dropped into 4 mL of deionized water and mixed evenly. Then 10 μL of the mixed nanoparticle aqueous solution was taken with a pipette and dropped on the surface of the silicon wafer. The SEM was used to test it, and spherical PSTPE nanoparticles with a diameter of about 130 nm were obtained. 1 mL of the nanoparticle aqueous solution of the above concentration was taken and dropped into a cuvette, and analyzed with a particle size analyzer, and PSTPE nanoparticles with a particle size of about 130 nm were found. Figure 4 shown.
[0038] Example 4
[0039] Effects of different materials on cervical cancer cells (HeLa) and rat glioma cells (C6)
[0040] In order to explore the tumor therapeutic effect of nanoparticles, different concentrations (25, 50, 100, 150, 200, 250 μg / mL) of novel Pillar[5]arene, PSTPE, and PSTPE-FA nanoparticle solutions were incubated with C6 cells and HeLa cells for 48 h. By comparison, it was found that PSTPE-FA nanoparticles had a stronger killing effect on cells and had a better anti-tumor effect. Figure 5 shown.
Claims
1. A glutathione response to release of SO 2 The prodrug has the following structural formula:
2. A tumor treatment drug, Features: Including the prodrug according to claim 1.
3. A nanoparticle, Features: It comprises an inner core and a hydrophilic outer shell, wherein the hydrophilic outer shell is wrapped around the outer core; the inner core is composed of the prodrug according to claim 1 and NH 2 -PEG-FA complex formation; The hydrophilic shell is a tetraphenylethylene connected to a glycol chain, and the structural formula of the tetraphenylethylene connected to a glycol chain is shown below:
4. Use of the nanoparticles according to claim 3 in the preparation of tumor therapeutic drugs.
5. A tumor treatment drug, Features: Comprising the nanoparticles described in claim 3.
Citation Information
Patent Citations
Liquid crystal composite gel, preparation method and application thereof and hydrogen sulfide gas detection method
CN109030478A
Pillar [5] arene-double calix [4] pyrrole chiral supramolecule as well as preparation method and application thereof
CN109232614A
Targeted and fluorescence tracing stimulation-responsive multifunctional nano-vesicle drug-loading system
CN111714456A
Synthesis method of polyethylene glycol side chain modified amphiphilic pillararene
CN113234219A
Preparation method and application of multifunctional nano-carrier with drug resistance and hypoxia / esterase dual response
CN113813394A
